BACE1 and Alzheimer disease: Notably, miR-29c-3p inhibitor and sh-BACE1 treatments could not completely eliminate the effects of miR-29c-3p and BACE1, so the Wnt/β-catenin level in the AD-EVs-inhibitor-sh-BACE1 group did not restore completely.